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Abstract
The Prenatal Assessment of Genome and Exomes (PAGE) project is a UK-wide study aim-
ing to gain a better understanding of genetic variants causing developmental problems dur-
ing pregnancy. A further aim of the study is to provide an evidence-base for the introduction
of prenatal whole genome and exome sequencing (PWGES) into prenatal diagnostics pro-
vided by the NHS, which is expected in 2018. This paper presents the findings of a qualita-
tive interview study undertaken with 20 health professionals and researchers involved in the
PAGE project, and explores their implications for understandings of ‘good practice’ in the
uses of prenatal genomics clinically. A number of critical issues are identified that will need
to be addressed in the development of a model of good ethical practice for prenatal geno-
mics: consent, management of expectations, return of results, and professional duties in the
context of PWGES. The analysis presented identifies and illustrates a great deal of com-
plexity and qualitative richness in these issues as they arise in the day-to-day work of geno-
mics professionals. Inclusive, critical discussion of these findings, together with the findings
from other empirical studies, normative analysis and scientific discoveries resulting from
PAGE, will be required to inform the development of appropriate guidelines of good ethical
practice that address the needs and concerns to be encountered in daily clinical practice.
Introduction
The introduction of genomic medicine into prenatal care and its potential to provide informa-
tion about the developing foetus is leading to a radical transformation of the practice of repro-
ductive medicine. Existing prenatal testing technologies–karyotyping, microarrays, single gene
and panel testing—enable the detection of certain chromosomal abnormalities (e.g. Down’s
Syndrome, Turner Syndrome) or single gene disorders (e.g. cystic fibrosis, muscular dystro-
phies). Such technologies target a limited range of defined abnormalities. Recent advances in
prenatal whole genome and exome sequencing (PWGES), however, with their greater
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resolution have the potential to detect a much wider range of genomic abnormalities [1–4].
Moreover, the insights such approaches provide into the genomics of the foetus and its devel-
opment also offer the potential for a better understanding of the nature and causes of structural
developmental abnormalities and can, hopefully, inform the development of effective
interventions.
The Prenatal Assessment of Genome and Exomes (PAGE) project is a UK-wide study (of
1000 families in which a structural abnormality has been identified in pregnancy but no diag-
nosis has been possible) aiming to gain a better understanding of genetic variants causing
developmental problems during pregnancy [5, 6]. Analysing in detail every single gene in the
parents’ and foetus’ DNA, the aim of PAGE is both to provide diagnoses for the recruited fami-
lies and to improve prenatal diagnostics, allowing better genetics-derived prognoses and more
informed reproductive decision-making [7]. A further aim of the study is to provide an evi-
dence-base for the introduction of PWGES into prenatal diagnostics provided by the NHS,
which is expected in 2018.
In addition to the scientific and clinical challenges of achieving this, it was recognised at an
early stage by the PAGE team that the introduction of new reproductive genomic technologies
in the context of the PAGE study, and also subsequently into clinical care, was likely to present
a number of practical ethical problems. These problems would need to be identified, under-
stood and carefully analysed in order to advance the development of models of good ethical
practice. In recognition of this, the PAGE study included embedded ethics support and advice
from the outset and also incorporated an ethics and social sciences research programme com-
bining a critical review of the existing literature on ethical issues in prenatal genomics [8], a
series of workshops with health professionals and researchers involved in PAGE and a qualita-
tive interview study exploring professionals’ views, experiences and concerns with regard to
PWGES.
In this paper, we report the results of the interview study undertaken with 20 health profes-
sionals and researchers involved in the PAGE project. The interviews explore the professionals’
views and experiences, and the ethical implications of these experiences for whole genome and
exome sequencing during pregnancy which is expected to be rolled out in clinic in 2018. More
specifically, professionals’ views were obtained on consent, management of expectations,
return of results, and professional duties in the context of PWGES. In this paper we present
themes that emerged in our analysis of the interviews. We conclude with a discussion of the
findings in the light of existing literature and reflect on ways forward for the development of
good ethical practice when WGES will be offered as part of prenatal care in the clinic.
Methods
In 2016 and 2017, 20 semi-structured interviews were conducted with health professionals and
researchers involved in the PAGE project. The interviews represent; a) ‘clinical’ perspectives
(n = 12) from those who recruited couples for the PAGE study and who are in contact with
women and couples in the clinical setting (5 midwifes, MW; 4 genetic consultants, GC; 2
patient representatives, PR; 1 research assistant involved in patient recruitment, RA); and b)
‘research’ perspectives (n = 8) from those involved in the development of the sequencing tech-
nology or the interpretation of the genomic data gathered (2 laboratory staff, LS; 6 genetic sci-
entists, GS).
The study was approved by the Central University Research Ethics Committee at the Uni-
versity of Oxford (R44366/RE001) and the Health Research Authority (IRAS project
ID:209003). Participants were recruited through the PAGE email list, which is a comprehen-
sive list of all health professionals and researchers (n = 90) involved in the project. Each
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participant received an information sheet about the study and written consent was taken prior
to the interviews.
Interviews were conducted by RH who is an experienced qualitative researcher. Each inter-
view lasted approximately 45 minutes, was audio recorded and transcribed verbatim. The aim
of the interview study was to better understand professionals’ experiences with the PAGE proj-
ect and more broadly their views on PWGES. For this purpose, the interviews explored profes-
sionals’ experiences with patient recruitment and informed consent, management of parents’
expectations, return of results, and professionals’ views on their duties in the context of
PWGES. The topic guide was conceptualised by both authors. The choice of interview topics
was guided by our initial literature review and two workshops, which were organised and facil-
itated by both authors as part of the ethics and social sciences research programme of PAGE.
Each workshop involved 30 professionals from PAGE and provided opportunities for the
exploration of practical ethical issues arising from both the literature and participants’ experi-
ences of using prenatal genomics.
The theoretical thematic analysis was driven by our interview questions and involved
numerous readings of the transcribed interviews. To begin, RH coded each segment of data
that was relevant to or captured interesting information about the questions in our interview
guide. The initial codes together with representative interview fragments were then reviewed
and recoded, and comparable recurrent themes and patterns in the data were identified and
refined. The themes that RH identified with regard to the interview topics were discussed on a
regular basis with MP as the analysis progressed. Both authors interpreted the coded data. Par-
ticipants were 80 professionals from PAGE, including some of the interview participants, and
other national stakeholders in the field of prenatal genomics. The conference provided an
opportunity for PAGE professionals to comment on the study and whether our findings and
interpretations adequately reflect their attitudes and experiences with the PAGE project, this
provided external feedback concerning the accuracy of the analysis.
Results
The complexity of achieving valid consent
The importance of consent is emphasised in both clinical and research guidelines [9–11].
Genomic research in the prenatal context, however, presents important challenges for the
achievement of valid consent because of the complexity of genomics and the intensity of emo-
tional stress for parents when foetal abnormality is detected or suspected during pregnancy
[8]. Our interviews showed that timing of the discussion and the way complex information is
transmitted are crucial to obtain valid consent.
The timing for seeking consent. The PAGE project, adopted a trio design. That is, the
study involved a comparison of the exomes of both parents and the foetus [7]. The foetal sam-
ple for PAGE was obtained from a sample taken during routine amniocentesis: an invasive
procedure offered as part of the clinical screening programme aimed at better understanding
abnormalities observed on ultrasound. Participants for PAGE were recruited at several centres.
In some, participants were recruited before amniocentesis, in others recruitment to the PAGE
project took place after amniocentesis had been completed.
Health professionals who recruited patients prior to amniocentesis first introduced the
PAGE project to them at the time the consultant offered the amniocentesis to the parents. For-
mal consent was obtained a few days later when the parents came back for the amniocentesis
procedure. Health professionals we interviewed, and whose centres had adopted this approach,
thought that the time given to parents between the initial contact and the actual recruitment
was very important:
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People need time to think about things, they want a day or two to go away and consider
whether they want to go ahead with the amniocentesis, and so in those situations we would
talk to them also a little bit about PAGE, give them the information to take away with them
and then when they come back [we would take consent]. (MW1)
One genetic consultant who recruited parents prior to amniocentesis expressed concerns
about post-amniocentesis recruitment (the approach taken by some other centres):
Once they [women]’ve had an amnio they’re in a bit of pain and [. . .] it’s almost like, ‘oh
thank God that test is done. I think they’d be more inclined to say, ‘Yeah do whatever you
want.’ (GC1)
However, other interviewees who were actually involved in recruiting parents after amnio-
centesis emphasised the benefits of this approach. They explained that it is very convenient to
recruit parents during the period following amniocentesis, while women are waiting to leave
the hospital after the intervention. They emphasised the benefit of making use of the parents’
waiting time, and reported that these situations facilitated recruitment.
Having said this, despite their tendency to emphasise the benefits of post-amniocentesis
recruitment, some of the interviewees acknowledged the emotional distress of parents in this
particular situation:
They are very vulnerable at that point [after amniocentesis]. The feedback that I’ve had from it
has been that it’s been very positive for them to have someone like me spending an extra 20, 30
minutes talking through this other process. (MW2)
Although parents who were recruited experienced the additional time professionals spent
with them as positive and reassuring, this is not the purpose of valid consent. The profession-
als’ acknowledgment of the parents’ vulnerability inevitably leads to questions about the extent
to which it might be more difficult to achieve valid consent in the context of post-amniocente-
sis recruitment. It also highlights the importance of paying particular attention to the need for
sensitivity to the emotional context [12].
Transmitting and comprehending complex information. Apart from these important
contextual features of prenatal genomics, health professionals also highlighted the challenges
of achieving valid consent to genomic testing per se and acknowledged its importance as an
issue.
Several midwives involved in recruitment for PAGE, questioned the ability of parents to
really comprehend the study information at a time when they are anxious about their
pregnancy:
We’re seeing families at an extremely vulnerable time. (MW2)
It’s quite a stressful time and quite an upsetting time so it can be difficult to sort of get a sense
of, you know, how much they really understand. (MW3)
Another midwife confirmed:
If you’ve just come here and there’s a suspected diagnosis, it’s been confirmed, and then you’ve
had that discussion about what it could mean for your baby [. . .] I don’t know how much you
take in. (MW1)
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This reflects the findings of other studies which have highlighted the difficulty of communi-
cating complex genomic information to a parent when they are under stress after a foetal
abnormality has been detected [13, 14].
Importantly, health professionals distinguished between parents’ understanding of the pro-
cedural aspects of participation and their understanding of the broader implications of prena-
tal genomics. They were confident that parents who consented to participate in PAGE
understood the procedure, but had doubts about parents’ understanding of the meaning and
scope of genomic research and medicine.
I think they [parents] fully understand the process that they have been enrolled into. I’m very
happy that they understand what they’ve signed up to as far as the process is concerned [. . .].
But genetics is a complex topic. So how much they properly understand when I’m talking
about finding specific genes, um. (MW2)
An interview study explicitly exploring the experiences of parents recruited for PAGE, con-
firmed the difficulties they faced in fully comprehending the meaning of genomics [13].
Reflecting discussions in the academic literature [8] about the best ways to assess how much
[parents] do fully understand (MW4), our interviewees argued that consent should be seen as
an ongoing process and participants should be provided with as much information as they
require at several stages along the journey from initial identification of the anomaly through to
genomic testing [15–17]. As one of the midwives stated:
I think it’s repetition as well. You know, if they’re able to talk to a few people about it and ask
questions, and have an ongoing opportunity to ask questions, they always have my contact
number and things so I think that kind of can help with continuing to develop their under-
standing. (MW3)
It was recognised however that continuity is sometimes difficult to achieve. Taking PAGE
as an example, as research staff changed throughout the project, continuity in the participant
contact, and hence in the consent process, could not always be guaranteed.
Management of expectations
The hope to ‘get an answer as to what went wrong’. In addition to the complexities of
genomics and the stressful context in which consent is obtained, the difficulty of communicat-
ing effectively about the implications of participation in the PAGE study was also compounded
by parents’ strong clinical reasons for choosing to participate in the study. According to the
health professionals interviewed, parents consented to the study because they wanted to
understand the abnormality observed in their foetus and its implications for future pregnan-
cies. Yet, it was clear from the outset that in many cases these expectations would not be possi-
ble to meet because; a) the interpretation of sequencing data to explain an abnormality seen on
a scan is difficult and cannot always be guaranteed [7], and b) as discussed above, it is difficult
to comprehensively communicate complex genomic information to parents. In order to avoid
disappointment and misunderstanding, health professionals involved in recruitment consid-
ered it to be crucial to discuss parents’ expectations and to ensure that the limits of genomics
were understood prior to taking consent [18, 19]. Our interviewees acknowledged the difficul-
ties of achieving this, however. They consistently reported that parents wished to get ‘an
answer as to what’s gone wrong with baby and why. [They] just want information’ (RA).
In the PAGE project, the challenges of interpretation and of establishing a reliable and
rapid pipeline for testing and feedback in the context of the lifetime of the project were
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recognised. Hence, a decision was made that results would not be returned to women and
their partners until after the pregnancy. This was explained, along with the reasons for it, at the
time of consent. The health professionals reported that this was not always well received by
some couples:
‘Some have raised their eyebrows and said, ‘Well what’s the point? If you can’t give me any
information, then I’m not sure we want to do this’ (MW4).
In general, however, interviewees reported that the majority of parents accepted this and
were mainly hoping to be given ‘information which could be relevant for future pregnancies or
for that child, if the child survives’ (MW3). The health professionals described that parents
‘want a good thing to come out of a bad situation’ (MW4) and ‘be able to contribute in some way
to the development of knowledge’ (MW3). The desire for more information which the profes-
sionals we interviewed reported as the main drive for parents’ participation in PAGE, was con-
firmed also by a study exploring the experiences of parents who took part in the PAGE project
[20].
Preparing for genomic findings and no findings. Health professionals reported that
even for those participants who acknowledge that feedback would only be relevant to future
pregnancies, the wish to get ‘to the bottom of what’s actually caused [the abnormality]’ (MW2),
sometimes led to high expectations that would be difficult or impossible to meet in genomic
research and medicine. This mirrors the findings of Cacioppo et al. who also observed frequent
discrepancy between parental expectations and actual results in genomic research studies [18].
The complexity of genomic information, and the challenges of establishing the meaning and
the interpretation of research results mean that, as one genetic consultant noticed, parents
who hope (as most of them will) to get an answer as to what is wrong with their baby need to
have their expectations managed prior to receiving results:
Sit down and talk them through it, because probably the most important thing is to have the
conversation before [you get] the results. (GC2)
Another interviewee, a genetic scientist, supported this, arguing that misunderstandings
and false expectations can often be avoided through thorough counselling:
The problems arise when people haven’t been told in advance, so then they look, ‘where did
that come from’? [. . .] I think it’s important that before the test is undertaken the counselling
explores some options with some examples potentially for them, because that makes it real for
people. (GS1)
One of the consultants interviewed emphasised the importance of discussing all possible
results with the parents in advance and of helping them think through possible decisions, or
‘exit strategies’, before feeding back results:
I detail the three possibilities [no finding, uncertain finding, finding] that might come, and I go
through each of those individual possibilities with the couple and make sure they almost have
considered an exit strategy for each of those. (GC1)
Notwithstanding these difficulties, health professionals who recruited parents were confi-
dent that, by the time consent was given, they understood the likelihood of receiving no further
information regarding the foetal abnormality identified,
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[. . .] because [the difficulty to get clear results] is explained well to patients initially and we’re
kind of managing their expectations. (MW4)
Within medicine there is always an element of uncertainty [. . .]. And I think most families
know that this testing might not give them an answer. (MW3)
The health professionals’ confidence with regard to their management of parental expecta-
tions can, to a certain extent, be explained by the set-up of the PAGE study, which required
that it was explained to parents at the outset that study results were to be fed back to them only
after pregnancy. Furthermore, PAGE opted to return only information on variants that
explained the structural abnormality seen on the ultrasound scan; that is, no incidental or
uncertain findings were communicated to parents [7].
Return of results
The interpretation of genomic variants in the prenatal context is difficult because the phe-
notype may not be fully detectable on screen or the penetrance of the variant is unknown
[21]. Sequencing the whole genome and exome of a foetus will generate a vast amount of
variants of which the significance is unknown or uncertain. Only few variants will be of
known significance. The still limited knowledge in the new field of prenatal genomics
means that it is difficult to target the sequencing, which implies that incidental findings will
be generated [13].
The right to know or not to know. The health professionals and researchers in the PAGE
project have had early experience with uncertain or incidental findings and reflected on their
wider implications for clinical practice. In the interviews, they placed important value on the
parents’ right to choose which information they wish to receive.
It’s [about] whether they have a choice about the information they want to know, which they
should have really. (MW1)
It was their view that even though in the particular research context of the PAGE study no
incidental or uncertain findings were being reported, once prenatal genomics is introduced
into clinical practice, it will not be right to hold back information:
‘If the information is out there, people are entitled to know it.’ (MW2)
Yet, they also acknowledged that:
[. . .] blissful ignorance sometimes is not a bad thing! [Only] if we do the test we’re going to
have to report it. (GC2)
The key concern for the professionals we interviewed was patient centred-ness. For exam-
ple, as much as they emphasised the importance to give parents the choice to decide what they
want to know, they also considered it important to also give them a choice not to know:
I don’t think we should force genetic information on people that don’t want it [. . .] an opt-in
and opt-out system would be good for that sort of thing. (LS1)
The ‘usefulness’ of information. Despite the fact that the health professionals and
researchers placed a great deal of emphasis on patient choice, most of them thought that the
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scope of the right to know should be limited by the ‘usefulness’ of information for the deci-
sion-making. ‘Usefulness’ here was mostly defined in terms of ‘clinical usefulness’.
I think [actionable findings] should definitely be fed back. [But if] the penetrance of a certain
mutation isn’t 100% [. . .], just because someone tells me I have a mutation doesn’t mean that
I’m going to die from that mutation.’ I think not feeding back [those] findings is largely the
right thing to do. (LS2)
One of the genetic scientists took an even stronger stance when arguing that feedback should
not be guided by the principle of autonomy if there is no clinical usefulness of the result:
I think it’s a wider context, and the autonomy is a positive side effect but I wouldn’t put it as a
priority. What is the clinical value of a Class 3 [variant where pathogenicity or lack of it cannot
be assigned based on current knowledge]? Not much [. . .] there’s nothing we can do about it in
the present time. (GS1)
Interestingly, some of our interviewees were willing to go further than limiting information
to that which was ‘clinically useful’ to that which was ‘useful’ in the specific context at hand.
That is, to the actual situation, the ‘here and now’. This was particularly true of health profes-
sionals who had face-to-face contact with parents. They tended to emphasise the importance
of only returning data relevant to the actual pregnancy or early childhood:
There is sometimes too much information, it’s not useful for the situation that they’re in. [. . .]
They either want to be prepared for when their baby is born so that they know the challenges
their baby might face, or it’s because they’re considering the option of termination. (GC3)
The broader impact of PWGES. In cases where the available genomic information would
not inform pregnancy or childhood decisions, but might be relevant to the later life of the
child, one of the midwives was more hesitant:
I think it’s quite easy if it’s a physical thing and it’s there from birth, but something that might
develop, that’s really opening up a whole different Pandora’s box, isn’t it really. (MW5)
More generally, where there was uncertainty about the future or actual significance and mean-
ing of the results, our interviewees argued that it would be better not to share this information.
According to some of the laboratory staff, ‘when we sequence there’s a fairly high error rate to the
technology we’re using’ and ‘there are a lot of technical hurdles that need to be overcome for [results
to be fed back during pregnancy]’ (LS1). Health professionals and researchers were concerned that
the uncertainty ‘could create more problems than we’re trying to solve’ (MW2) and ‘create unneces-
sary anxiety’ (MW4). Unless the broad public will be ‘educated’ and ‘understand [genomics] at a
basic level through media or other influences’ (RA), they considered it difficult to give parents every
information, particularly where this was deemed it to be of no clinical utility.
Taken together, this shows that health professionals and researchers believe that patients
choices about information and feedback should determine what information is returned and
when, but that the scope of their autonomy ought to be limited to information with clinical rel-
evance. Our interviewees acknowledged the challenges of deciding on feedback about uncer-
tain information within the context of even this more limited scope, however.
Turnaround times. Within the context of the PAGE project itself, study results were fed
back only after pregnancy. Health professionals expressed some concern about the fact that
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feedback within the research context was taking around a year. This was particularly difficult,
they argued, for parents who had miscarried:
We’ve had some patients who are sort of OK not to find out during the pregnancy but they
don’t want to find out a year later because [. . .] they will try to move on and forget about what
happened. (GC4)
A study exploring parents’ experiences within PAGE [20] confirmed that the long turn-
around time in the study was difficult for some of the parents recruited.
Another difficulty faced by health professionals in PAGE arose in those situations in which
they had to contact parents who–despite the earlier anomaly at ultrasound–had had a seem-
ingly healthy baby, but where the WGES has shown an association between a genetic variant
and the initially detected structural abnormality:
You can’t really just ring them up and say, ‘Oh by the way, is your child normal now?’ [. . .] do
you just poke all of that [worry] up with a stick when you come back with a result? Are they
grateful for it? (GC1)
When prenatal genomics is introduced into clinical practice more widely–from later in
2018, results will be fed back during pregnancy in order to inform parental decision-making
and problems related to a long turnaround time will not arise in the same way.
The attitudes and experiences of the health professionals and researchers reported in
this paper mirror and confirm, at least in part, published accounts of patients’ views on
the return of genomic results. Further analysis of these findings in the light of normative
arguments will make important contributions to the development of ethical frameworks
of good practice and help answering the question as to what findings ‘ought’ to be fed
back.
Professional duties in the context of PWGES
The duty to improve knowledge and facilitate informed decisions. Despite the difficul-
ties discussed above, overall, health professionals and researchers valued PAGE, and more
broadly prenatal genomics. The biggest benefit associated with PWGES was the possibility it
offered to provide answers to parents that would not otherwise be available.
Often our women will have an invasive testing, have a karyotype or array and actually don’t
get any answers or explanations, and I think PAGE can add an additional layer to that and
give us a bit more information. [. . .] There is a thirst for knowledge and a thirst for explana-
tion of why some of these babies do develop problems in pregnancy. (MW4)
Our interviewees emphasised the importance of PWGES as a way of helping parents to pre-
pare for difficult situations and make informed decisions:
[It] gives them a much better idea of how it will affect their children [. . .] then preparing and
coping with it might be better. (GC4)
[It offers] more information to make a more informed choice. (PR1)
They perceived the provision of information not only as one of the benefits of PAGE, but
also as one of their duties towards parents:
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I have an obligation to make sure that the parents have all the information they need to make
the best decision for their child and their wider family if they’ve got one. (GC3)
Another important aspect associated with PAGE, was the opportunity to ‘find out more
about how we can avoid major abnormalities’ and ‘eradicate [serious disability] not something
like Down’s syndrome, but where I see sort of quadriplegic children, that’s not the same thing.’
(MW2). That is, to help future parents and children as well as those currently being seen. Gen-
erally, the interviewees, particularly the researchers, saw knowledge generation and advance-
ment of technology as their duty, and as the major advantage of PAGE:
PAGE will progress the technology or help to establish the new technology of using next genera-
tion sequencing for this kind of diagnosis. (GS2)
Both clinical and scientific staff considered it as their obligation to contribute to the growth
of knowledge and the development and improvement of technology:
I think as a scientist I’m in favour of progress and change, and I want to work on things that
are going to improve the world and the way healthcare is operated. (LS1)
I think if we have the potential to find out information [. . .] we can’t really shut the door now,
the genie’s out, we need to refine it. (MW4)
The duty to protect patients from technology. Despite their enthusiasm and their sense
that research and innovation are important parts of their work, the health professionals and
researchers we interviewed were realistic and recognised the importance of paying close attention
to their social and ethical implications. Amidst the enthusiasm about innovation, some profession-
als mentioned that the limits and scope of the new technologies require to be discussed by society:
We have to progress, we can’t hold ourselves back unnecessarily, and we need to make a deci-
sion as scientists, as ethicists and as a society as to what we think is an acceptable use of this
technology. But I absolutely think that it’s right to push the boundaries and to do the best job
that we can for these people. (LS1)
Also others expressed concerns about the fast evolving field of genomics:
It is opening a sort of new chapter in medicine and we’re not fully understanding the implica-
tions. [. . .] I think there is the potential for stress and anxiety if we don’t quite understand
what we’re dealing with [. . .] are we opening a can of worms?
(MW4)
The risk of ‘opening a can of worms’ as a metaphor for the vast amount of data that cannot
be fully understood and the yet unknown implications of prenatal genomics, was mentioned
by several interviewees. One of them also referred to the ‘potentially toxic knowledge’ (GC1)
WGES may generate. Such knowledge was discussed as particularly problematic in the case
where WGES would be offered by private providers without comprehensive counselling:
I think what’s worrying me is that [in the private sector] it’s not under a controlled environ-
ment. [. . .] The risk that is would become too easily accessible [. . .] not for the right reasons
and not properly explained. (GC2)
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In order to prevent the loss of control over new technologies, one of the interviewees, a
genetic consultant, reminded of their obligation to continuously question the aim of scientific
progress:
[It] is our job to protect the patients from scientists, almost. Because if you ask a scientist [. . .]
their eyes will light up and they will just go deep down a rabbit-hole, ‘Oh wow, let’s look even
further, let’s dig, let’s lift up the mattress and properly look underneath! (GC1)
The duty to provide education and resources. Other interviewees also mentioned the
role education plays in how technology is used and understood. They acknowledged their obli-
gation to contribute to this education:
We can influence the course of action by providing open, clear information, and not hiding evi-
dence to others; just facts and data and then people can make up their minds. [. . .] I think our
responsibility is also to train the clinical teams, the frontline people, to make sure they have the
facts right and they understand what they are offering the patients or not. [. . .] I think mostly
of our responsibility is how we educate people about using this information. (GS1)
However, many of the interviewees were concerned about how to guarantee education in
view of the complexity of the fast evolving field of prenatal genomics and increasingly limited
resources in the National Healthcare Service (NHS):
The huge challenges for us introducing this technology, is education [. . .] there would have to
be almost a mass, you know, a mass discussion about prenatal ethics, about education. [. . .] if
you are delivering this test then you have a responsibility. (GC1)
We don’t have enough genetic counsellors working prenatally [. . .] we do not have the support
that’s required. [. . .] You do need the resources there [. . .] the whole genomic testing will be
extremely costing. (PR2)
Limited resources are an issue also in relation to access to genomics services. While the
costs of the sequencing itself have dropped in the past years, the costs of data management
including analysis, interpretation and storage are growing [8]. In the interviews, the genetic
scientists expressed some concern about equal quality standard across the country, whereas
clinical staff expressed worries regarding data protection:
It does slightly worry me on the other hand that we’ve got all this information and we’re storing
it, and it’s anonymised but it’s going out of the country [. . .] it’s meant to be secure but I’m not
sure anything is secure now. (MW5)
Our interviewees emphasised research companies’ and public authorities’ obligations to
meet the costs for data management, as they were worried that otherwise the quality of the
information obtained as well as data protection cannot be guaranteed [22].
Discussion and ways forward
As the PAGE study comes to an end, it is expected that PWGES will increasingly be available
through the NHS from 2018. Our interviews have highlighted important questions and practi-
cal ethical issues that will need to be taken into account in the development, implementation
and evaluation of models of good ethical practice in prenatal genomics. These aspects overlap
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to some degree with those identified in the preceding literature review on PWGES [8] but are
given a much greater degree of nuance and depth by the analysis presented above. From a
bird’s eye view, the issues at stake are: consent, management of expectations, return of results
and professional duties in the context of PWGES. Our findings illustrate a great deal of com-
plexity and contextual variation across these issues. In the following we reflect on these issues
in the light of our interviews as well as existing literature, and consider what might be required
to establish models of good ethical practice in the use of prenatal genomics clinically.
The analysis presented here highlights the fact that parents’ consent to undergo PWGES is
strongly influenced by the timing of and context within which information about this test is
provided. It is also apparent that parents’ understanding of complex genomic information can
be framed by unrealistic expectations and the emotionally distressing situation parents find
themselves in when foetal abnormality has been detected. As our interviewees confirmed, it is
clear that any effective approach to consent is going to need to be interactive and on-going,
and that time needs to be given to parents to consent. Only then will it be possible, to provide
information that is tailored to the parents’ needs and receptivity at an emotionally stressful
moment and as part of an on-going conversation [23]. The required model of consent will
need to be a ‘communicative process that is consent-in-action’ and an ‘opportunity to discuss
the return of results in advance’ [24]. For this purpose, and recognising the time-constraints of
pregnancy, continuity in the care and support provided to parents need to be guaranteed.
Guidelines on the implementation of PWEGS will be required to help health professionals, but
also researchers, to make structured and well-considered judgements about ‘when’ the test
should be offered, ‘how’ complex information is communicated and ‘what’ parents actually
understand.
Similarly, a one-size fit all approach regarding the return of results is unlikely to be appro-
priate in the light of different patient experiences and preferences and in the context of the var-
iability of the definition of clinically or personally ‘useful’ data. Studies have shown that
patients wish to have a choice in decisions about what information is fed back [21, 22]. There
are some interesting tensions, however. For example, while some patients might wish to
receive only ‘clinically’ useful information, other patients might wish to receive every informa-
tion they personally judge useful; in some cases, this may include variants of uncertain signifi-
cance or even their whole sequence. These empirical findings challenge a one-size-fit-all
approach, and call for involvement of the parents in pre-test counselling discussions [23].
However, some limits will clearly need to be placed on what information should be returned in
order to both be manageable in the clinical setting and also to avoid harm to parents or the
future child [25]. There are a number of important and, as yet, unresolved questions about
how feedback ought to be managed. To what extent should feedback focus solely on informa-
tion relating to the identified anomaly on ultrasound? To what extent should broader findings
be returned? How should such decisions be made and by whom? It is likely that feedback will
only take place where there is ‘clinical utility [26, 27]. In the prenatal context, however, it is
often difficult, with the exception of few conditions, to predict or foresee whether and if so,
how, an identified variant will affect the child later in life. It is clear that these are not solely sci-
entific or clinical questions but are strongly value-laden [8]. It might be that, for example, an
agreed list of genomic variants to be reported could be produced, similar (in approach rather
than in specific content) to the recommendations of the American College of Medical Genetics
and Genomics [27]. However, as Green et al. acknowledge, it may be “difficult to reach con-
sensus on a specific list of variants that meet a threshold for disclosure” [27] and appropriate
patient-centred variation may also be an important consideration. Whichever approach is
adopted, possible findings as well as limitations of what information will be reported should be
discussed during counselling and prior to taking consent [28]. Key to this is going to be the
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management of expectations to reduce conflict and uncertainty in the relations between clini-
cians and parents [18].
It may be that confidence in clinical practice or research in prenatal genomics may best be
built by providing clear knowledge and improving technology. Our interviewees felt a strong
obligation to advance genomics medicine through research participation in order to facilitate
the development of better diagnosis, and ultimately also treatment for genetic conditions. Yet,
they were aware of the risks of over-emphasising the benefits of genomics as well as driving sci-
entific advances without carefully assessing the broader individual and social implications
[29]. The health professionals and researchers of PAGE felt that patients need to be protected
from ‘toxic’ knowledge [30] and technology. One way of doing this is by providing broader
genomics education. Given the interviewees’ comments above about the important role of
counselling, it is clear that sufficient resources need to be made available not only for high
quality technology and data curation but also for effective and well-resourced counselling in
the prenatal context. This includes the provision of sufficient numbers of staff, available time
for continuous information, and education of staff as well as the broad public [31]. Finally,
putting in place multi-disciplinary national review panels validating the variants identified in
order to guarantee coherent results across the country has proven very useful and consensus-
building in the PAGE study. Such panels have also been adopted in other studies such as the
UK’s 100,000 Genomes Project allowing for equal quality standard of data interpretation
across the various research sites [32].
Conclusion
The interviews with health professionals and researchers involved in the PAGE project
reported here have highlighted a number of critical issues that need to be addressed in the
development of a model of good ethical practice and implementation of prenatal genomics ser-
vices in the UK National Health Service: consent, management of expectations, return of
results and professional duties. Our findings have highlighted some of the complexity and
qualitative richness of these issues as they arise in the day-to-day work of genomics profession-
als. As prenatal genomics moves into clinical practice, guidelines need to be developed to
address the following questions: What is required for effective, valid consent for prenatal geno-
mic testing? When and how should consent be sought? What and how much information
should be fed back to parents? What data should be stored, how, and with whom should it be
shared? What can be done to guarantee equal quality standard of data interpretation and vali-
dation across the country? What are the obligations of health professionals, researchers and
other stakeholders to patient/participants (and their families)? What and how many resources,
in terms of staff, time and education, are needed to secure high quality counselling, and how
can this be achieved? In order to address these questions, the empirical findings presented in
this paper as well as those by other researchers in the field need to be taken into account and
further discussed in the light of normative arguments. In a next step, various stakeholders in
the field, clinical staff, scientists, and patients, in collaboration with ethicists and sociologists
should be involved in the development of appropriate guidelines of good ethical practice that
address the needs and concerns to be encountered in daily clinical practice.
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